Grant Details

General Overview

Grant Information

Grant name: Assay Validation of High Quality Markers for Clinical Studies in Cancer

Funding organization: National Cancer Institute (NCI), National Institutes of Health (NIH)

Total funding amount: Up to $250,000 per year

Duration: Maximum project period of 3 years

Primary objective: To validate biomarkers and assays for cancer detection, diagnosis, prognosis, and treatment response

Key stakeholders: Scientific investigators, oncologists, statisticians, clinical laboratory scientists

Funding source: Federal government

Funding type: Cooperative agreement

Significance: Addresses critical barriers in cancer research by validating assays for clinical use

Grant frequency: One-time funding opportunity

Organizational Aspects

Eligibility Criteria

Eligible organization types: Higher Education Institutions, Nonprofits, For-Profit Organizations, Local Governments, State Governments, County Governments, City or Township Governments, Indian/Native American Tribal Governments, Federal Government agencies, and others

Specific qualifications: Assays must be analytically validated

Geographic location: U.S. based organizations

Previous relationship with funder: Not specified

Organizational maturity: Not specified

Scope and Focus

Project Characteristics

Primary focus areas: Cancer detection, diagnosis, prognosis, and treatment response

Target beneficiaries: Cancer patients and healthcare providers

Geographic coverage: U.S.

Expected outcomes: Clinical validation of assays

Sustainability expectations: Not specified

Technical Details

Requirements

Technical expertise: Must have experience in assay validation

Infrastructure: Access to clinical laboratory facilities

Team composition: Must include clinical investigators and laboratory staff

Quality standards: Assays must meet CLIA certification if used for medical decision-making

Financial Structure

Funding Details

Budget range: Up to $250,000 per year

Eligible costs: Direct costs related to assay validation

Matching fund requirements: Not specified

Payment schedule: Not specified

Timeline and Implementation

Key Dates

Open date: January 19, 2024

Application due dates: Multiple deadlines until October 14, 2026

Earliest start date: February 20, 2024

Compliance and Requirements

Regulatory Compliance

Regulatory compliance: Must adhere to NIH policies

Data protection: Must comply with applicable regulations

Ethical standards: Must ensure ethical conduct in research

Application Process

Submission Instructions

Required documentation: Follow the Research Instructions in the Application Guide

Application procedure: Submit through Grants.gov

Evaluation criteria: Scientific merit and relevance to cancer research

Special Considerations

Unique Aspects

Focus on existing assays rather than new technology development

Encouragement of multidisciplinary collaboration

Previous Funding Patterns

Historical Context

This is a reissue of a previous funding opportunity (PAR-20-314)

No specific historical recipient data provided

Grant Details

cancer biomarkers clinical studies healthcare research assay validation oncology clinical trials NCI NIH
Assay Validation of High Quality Markers for Clinical Studies in Cancer
PAR-23-314
NIH Grants
EDU NGO PUBLIC OTHER
US
HEALTHCARE RESEARCH
DEVELOPMENT
0-10 11-50 51-250 251-500 500+
SDG3
FUNDING RESEARCH_DEVELOPMENT
None
250000.00
None
250000.00
USD
None
Oct. 14, 2026, 5 p.m.
Not specified